Decoy Therapeutics is trading at $1.51, down 6.2%, as a resale-share filing may be weighing on shares, though reports do not establish it as the cause. - A recent filing registered up to 2.37 million existing shares for resale by selling stockholders; the company is not selling them and will receive no proceeds. - Biotech shares are under pressure, with XBI down 2.04%; higher yields and oil prices add macro headwinds. No trading-volume details were available.